Table 3.
| c.95 A > G carriers n = 17 | c.95 A > G/RH n = 17 | c.95 A > G/c.95 A > G n = 17 | |
|---|---|---|---|
|
LVEDV/[mean] n > 95% CI |
1.05 (0.19) 2 (12%) |
1.01 (0.21) 3 (18%) |
1.12 (0.18) 5 (29%) |
|
LVESV/[mean] n > 95% CI |
1.22 (0.31) 5 (29%) |
1.17 (0.28) 2 (12%) |
1.22 (0.22) 3 (18%) |
|
LVSV/[mean] n > 95% CI |
0.97 (0.17) 1 (6%) |
0.94 (0.21) 1 (6%) |
1.06 (0.21) 3 (18%) |
|
LVCI/[mean] n > 95% CI |
1.06 (0.17) 2 (12%) |
1.04 (0.26) 1 (6%) |
1.05 (0.22) 4 (24%) |
|
LVEF/[mean] n < 95% CI |
0.92 (0.07) 4 (24%) |
0.92 (0.08) 3 (18%) |
0.94 (0.07) 3 (18%) |
|
LV mass/[mean] n > 95% CI |
0.91 (0.17) 1 (6%) |
0.87 (0.19) 0 |
1.03 (0.20) 1 (6%) |
|
LV Peak Filling Rate/[mean] n > 95% CI |
1.07 (0.22) 0 |
1.00 (0.30) 0 |
1.23 (0.29) 0 |
Data are presented as n (%) or mean ± standard deviation. Comparisons include ratios to published means and 95% percentiles and numbers (%) above respective percentiles. CI, confidence intervals; [mean], published mean value; LV, left ventricle; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; LVSV, left ventricular stroke volume; LVEF, left ventricular ejection fraction; c.95 A > G carriers, heterozygote; c.95 A > G/RH, compound heterozygotes for c.95 A > G and the risk haplotype; c.95 A > G/c.95 A > G, homozygote. *P < 0.05. A p-value < 0.05 are considered significant.